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Antti Valli 
SELECTION AND SCREENING OF 
SINGLE CHAIN VARIABLE 
FRAGMENT ANTIBODIES AGAINST 
HUMAN PARECHOVIRUS 1 
This Bachelor’s Thesis was written in the Department of Virology and Department of 
Biochemistry/Biotechnology at the University of Turku. The goal of the thesis was to select and 
screen antibody binders against human parechoviruses from synthetic scFv human antibody 
libraries. The phage display method was used to express scFv molecules on the surface of phage 
particles. These were subsequently used in three consecutive panning rounds to identify scFv 
binders to recombinant viral protein (human parechovirus VP0) that was biotinylated and 
immobilized onto the bottom of streptavidin coated wells. ScFv phage particles that bound to 
target protein were inoculated onto bacteria to enrich the phage population and purified, and 
analyzed further by Eu-Delfia. Increase in specific signals against controls between panning 
rounds was regarded as a sign of a successful isolation of a phage preparation containing scFv 
binders specific for viral proteins. The scFv gene was subcloned from phage library to vector 
pLK06FT, which encodes a scFv-AP-His-FLAG fusion protein. Individual cell clones were 
identified and scFvs were isolated and screened on pNPP-ELISA. Positive clones were saved for 
further assay and sequence verification. 
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ABBREVIATIONS 
Ags  Antigens 
AIROPico EU-project, abbreviation stands for Academia-Industry Re-
search and Development Opportunities for Picornaviruses  
BCA Bicinchoninic acid assay aka Smith assay 
BSA  Bovine Serum Albumin 
DNA  Deoxyribonucleic acid 
ELISA Enzyme-Linked Immunosorbent Assay 
Eu-Delfia Eu labelled Dissociation-Enhanced Lanthanide Fluorescent 
Immunoassay 
GST  Glutathione S-transferase, helper tag in protein purification 
HPeV-1  Human parechovirus 
PBS  Phosphate-buffered saline 
pNPP para-Nitrophenylphosphate = chromogenic substrate for acid 
and alkaline phosphatase in ELISA 
RNA  Ribonucleic acid 
scFv Single chain variable fragment 
VP0 Human parechovirus coat protein 0 
scFvP Synthetic human antibody library for protein selection 
scFvM Multipurpose synthetic human antibody library  
TBT-0.05 Panning buffer PBS/BSA with 0.05 % Tween 
RT Room temperature (approximately 20 °C) 
AP  Alkaline Phosphatase 
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1 INTRODUCTION 
The practical work was done at the Department of Biotechnology and the Department of 
Virology at the University of Turku. The research project was part of an EU-funded 
AIROPico project, which stands for Academic-Industry R&D Opportunities for Picorna-
viruses. The goal of the study was to identify antibody binders for different picornavirus 
types to be used in medicine or in diagnostics. Two phage display antibody libraries were 
used to identify potential picornaviral binders. The phage display method was used to 
express scFv molecules on the surface of phage particles. These were subsequently 
used in three consecutive panning rounds to identify scFv binders against recombinant 
viral proteins. The pool of phages was inoculated onto Escherichia coli to enrich the 
phage population. ScFv coding genes were subcloned into a vector, which encodes a 
scFv-AP-His-FLAG fusion protein. The vector was inoculated onto E. Coli and individual 
cell clones were identified. These cell clones were used to produce mono-specific scFv 
antibodies against picornaviruses. The scFv antibodies were analyzed by ELISA and 
plasmids encoding the antibodies were sequenced for the binding region. The process 
behind the thesis is presented in Figure 1 
 
Figure 1. Process flow chart of the thesis. 
1.1 Picornaviruses  
Picornaviruses are very small (about 30 nm in diameter), non-enveloped, spherical and 
positive stranded RNA viruses. Picornaviruses belong to order Picornavirales and to 
Family Picornaviridae. The family consists of 29 genera (Appendix 1). Picornaviruses 
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cause a wide range of diseases from asymptomatic or mild flu-like illnesses to serious 
syndromes such as aseptic meningitis, encephalitis, febrile rash illnesses, conjunctivitis, 
herpangina, myositis, myocarditis and hepatitis. They are also the most common patho-
gens in human, which cause respiratory tract illnesses and the hand, foot, and mouth 
disease (Lutwick 2014). Parechoviruses cause mild gastrointestinal or respiratory ill-
nesses and have been implicated in cases of myocarditis and encephalitis in young chil-
dren (Wolthers et al. 2008). In one study, a seroprevalence of HPeV-1 was found to be 
97%, which indicates that almost all individuals have encountered HPeV-1 infection in 
the childhood (Joki-Korpela et al. 2001). Picornavirus capsid consists of a tightly packed 
icosahedral arrangement of 60 protomers. Each protomer consists of four capsid pro-
teins (VP1-4, which all derive from the cleavage of a large viral polyprotein (Figure 2). 
Unlike other picornaviruses human parechoviruses do not have separate VP4 protein 
but instead they have VP0, which is a fusion protein containing both VP2 and VP4 (Vi-
ralzone.org, 2016). 
 
Figure 2 the General structure of picornaviruses (www.expasy.org/viralzone, Swiss In-
stitute of Bioinformatics, 2014). 
1.2 Phage display and panning 
Phage display is an in vitro technique where target protein, e.g. an antibody molecule is 
expressed on the surface of phage particlet in fusion to phage coat protein (Hoogen-
boom et al. 1998). Phage display can be used as a library, which means that it may 
contain up to 10E11 different phage particles displaying different target antibodies on the 
phage surface. Identification of a binding of any displayed antibody to a specific target 
protein can be done using the phage display panning method. This means a coating of 
the target antigen onto plate or beads, and then incubating a phage display library in the 
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wells or with beads. Non-binders can be removed from the mixture allowing only binder 
phages to be isolated. These phages can be enriched in E. Coli to generate a new pool 
of phage particles to be used in the next round of panning. This time the new pool con-
tains a large number of target-specific antibodies. Typically, three rounds of panning are 
performed (Figure 3). Compared with standard hybridoma technology for production of 
target-specific monoclonal antibodies, phage display is a much faster method (Carmen, 
Jermutus 2002). In addition, it is possible to select antibodies, which would never be 
produced in immunological reactions in the immunized animal.  The panning process 
can also be altered to direct the selection of specific antibodies and their affinity can be 
improved by phage display affinity maturation technique. 
 
Figure 3 Phage display round (cycle) (Hoogenboom et al. 1998) 
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2 MATERIALS AND METHODS 
Three panning rounds (Figure 4) were conducted to enrich a phage preparation with 
specific scFv antibodies against recombinant virus coat protein. In each panning round 
E. Coli XL1 Blue cell line was infected with enriched scFv phage preparation, which was 
subsequently analyzed in Delfia assay using Eu-labelled detector antibodies generated 
against phage particles. After second and third rounds of panning, scFv genes were iso-
lated from phage DNA and were subcloned into the screening vector, pLK06FT. Individ-
ual bacterial cell clones were picked from selection plates, cultivated, and scFv fusion 
protein production was induced for further analyses. 
2.1 Phage display 
GST-tagged recombinant virus protein was produced and purified in E. Coli. Recombi-
nant HPeV-1-VP0-GST protein was used in phage display to find binders against it. In 
phage display panning, synthetic human antibody libraries scFvM and scFvP were used. 
ScFvM with a functional diversity of 6E9 phages and scFvP with a functional diversity of 
3E9 phages have phages containing identical antibody VL-VH framework, but they differ 
in CDR-H3 site from each other (Huovinen et al. 2013). CDR-H3 is the binding site for 
the target antigen and therefore the most important region in scFv antibodies. 
2.1.1 Biotinylation of antigens 
In the panning protocol, biotinylated antigens were used. For the elimination of the amino 
groups which could interact with the biotinylation reaction, the storage buffer (Tris) was 
changed to PBS-buffer by performing ultrafiltration five times using Amicon Ultra-4 Cen-
trifugal filter with 10 kDa molecular weight cut-off. After the buffer exchange, anti-gens 
(HPeV-1-VP0-GST and GST control) were biotinylated using Thermo Scientific EZ-Link® 
Sulfo-NHS-SS-Biotinylation Kit. Biotin concentration used was 0.1 mM. De-salting col-
umns NAP-5 and NAP-10 were used to exchange the buffer. Absorbance with 280 nm 
wavelength of antigens used were measured before and after biotinylation (Table 1) 
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2.2 Panning 
Phage display selections were carried out in three rounds by using biotinylated antigens 
and magnetic streptavidin M280 Dynabeads. For negative control, streptavidin coated 
wells (2) and Neutravidin beads (3) were used. 
Panning round 1 
In first panning round synthetic human antibody libraries scFvP and scFvM were pooled 
together.1 mL of each phage library was precipitated by PEG/NaCl to get rid of storage 
glycerol, pelleted and resuspended in panning buffer TBT-0.05 to reach phage concen-
tration of 5E12 phage particles / mL. 
Panning protocol is presented in (Figure 4). Magnetic Streptavidin M280 Dynabeads 
(Invitrogen) conjugated particles were prewashed and coated with bio-Ags by incubating 
30min in rotation at RT. The beads were washed three times with TBT-0.1 and one time 
with TBS using volume of 1 mL. Diluted phages from passively coated panning were 
added onto negative selection GST coated beads and incubated in rotation for 1 h at RT. 
Dynabeads were immobilized with a magnet and phages were transferred onto VP0-
GST coated beads, free biotin and GST were added and beads were incubated in rota-
tion over night at 4 °C. Beads were again immobilized with a magnet and supernatant 
was discarded. Beads were washed three times with TBT-0.1 and one time with TBS to 
avoid any inhibition in trypsin elution because of BSA in TBT buffer. Sigma Trypsin was 
added onto beads and incubated 15 – 30 min at RT. Phages were collected from super-
natant and Gibco Soybean trypsin inhibitor 10 mg/mL diluted 1:100 in TBS was added 
onto phages equal volume to eluted phages. 
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Figure 4. Flow chart for HPeV-1 VP0-GST panning 
Cell infection 
Escherichia coli XL-1 Blue cells were inoculated into SB medium with 10 µg/mL tetra-
cyclin and 0.2 % glucose. Cells were grown at 37 °C, 300 rpm until OD600 was around 
0.5 estimated by a naked eye. E. Coli cells were infected with eluted phages and incu-
bated at 37 °C for 30 min to allow infection. Dilution series (10e-2, -3 and -4) were per-
formed to calculate the phage output. XL-1 Blue without infection was plated as a nega-
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tive control. 100 µL of dilutions were plated on LA small plates with tetracyclin, chloram-
phenicol and glucose. Plates were incubated overnight at 37 °C. The rest of undiluted 
cells were centrifuged at 4000 rpm for 10 min at 4 °C, pellets were resuspended in 5 mL 
of SB media and all of it was plated on large square LA-Tet-Cm-Glu plates. Plates were 
incubated overnight at 37 °C.  
E. Coli cells were collected from big square plates by adding 15 mL SB medium and 
gently scraping cells off the plate. 20 % of glycerol was added and glycerol preps were 
stored in -70 °C. Phage output plates were calculated and finally panning round one 
phage output was calculated. 
For the phage production from glycerol prep, medium of 20 mL SB, 1 % glucose, 5 mM 
MgCl2, 10 µg/mL tetracyclin and 25 µg/mL chloramphenicol was prepared. The amount 
of glycerol prep addition was calculated to reach starting OD600 0.05. Cells were culti-
vated in 37 °C, 300 rpm until OD600 = 0.5. VCS M13 helper phage (Stratagene) were 
added and carefully mixed avoiding breaking the pilus. Cells and phages were incubated 
30 min at 37 °C to infect the cells. Infected cells were pelleted by centrifuging 10 min, 
4000 rpm at 4 °C in Eppendorf 5810R swinging bucket centrifuge. Cells were transferred 
into a fresh batch of medium like above but without glucose. After 1 h growing period, 70 
µg/mL of kanamycin and 100 µM of IPTG was added to induce the phage production in 
E. Coli. Cells were grown overnight at 26 °C, 250rpm, pelleted down and discarded. 
Phages in supernatant were precipitated by adding 1/5 volume of PEG/NaCl solution 
and incubating on ice for 30 min. Phages were pelleted by centrifuging 10000 g, 20 min, 
4 °C and resuspended into 1 mL of TSA/BSA buffer. To make sure that no cells were 
left, precipitation with PEG/NaCl was performed again until the solution was clear. Phage 
stock for panning round two was at this point ready. The phage titer was measured by 
an Absorbance method, which roughly stipulates that 1 OD265 equals 1.23E13 phages 
/ mL. The phage stock was diluted to water in 1:50 dilution and TSA/BSA was used as a 
blank.  
Panning round 2 
For panning round two negative selections against SA and GST for VP0-GST were per-
formed by using Streptavidin strips (yellow colored). SA Strips were prewashed with 
TBT-0.05. Phages from the panning round one were diluted to 10E11 in TBT-0.05 and 
added onto strips and incubated 1 h at RT in slow shaking (Negative selection against 
SA). After incubation, phages were transferred onto GST coated streptavidin strips and 
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incubated for 1 h at RT in a shaker (Negative selection against GST). Negatively selected 
phages were transferred onto prewashed and bio-VP0-GST coated Dynabeads and in-
cubated 1 h at RT on rotation. Phages were discarded and beads washed three times 
with 1 mL of TBT-0.1 and one time with TBS. From this point onwards the panning was 
performed like in the previous round one. 
Panning round 3 
In the panning round three phage concentration used was 10E11. The final round of 
panning was performed using HPeV-1-VP0-GST and CsCl-purified HPeV-1 as targets.  
6 µg per well of purified HPeV-1 was coated on Nunc Maxisorp 96 well plate in 150 µL 
per well of 50 mM HCO3-/CO32+ buffer (pH 9.7) and incubated at 4 °C overnight. After 
overnight incubation, the plate was washed two times with PBS + 0.1 % Tween. Plate 
was blocked with 2 % BSA in PBS and incubated 1 h in a shaker. Plate was washed four 
times with PBS + 0.1 % Tween. For the negative selection in non-coated wells, only the 
wash buffer was added. The background was done without coating and only by blocking 
with 2 % BSA in PBS. First diluted phages from the panning round two were added onto 
negative selection wells and incubated 1 h at RT in a shaker. The wells were washed 
four times with the wash buffer and the phages were transferred to the next row. The 
plate was incubated 1 h at RT in a shaker and washed four times with a wash buffer. 
The elution was performed as in panning round two. 
HPeV-1-VP0-GST panning was performed as in panning round 2 with two exceptions. 
Neutravidin beads without any antigen coating as a background were used and infected 
cells were plated on rounded medium sized LA-plates. 
2.2.1 Analysis of binding of phage library to target antigen by Delfia 
Time-resolved fluoroimmunoassay was used to measure the binding of phage prepara-
tion obtained from panning rounds 2 and 3 to GST, VP0-GST and HPeV-1. Biotinylated 
antigens were coated onto prewashed streptavidin microtiter plate. 200 ng per well of 
antigens were added with 200 µL of Kaivogen Red Assay buffer to reach saturation level 
of 75%. The plate was incubated for 30 min at RT in a shaker. The plate was washed 
four times with Kaivogen Wash buffer. 125 ng/mL per well of a labelled anti-phage anti-
body Eu-N1-Mab (N1EuαVCSM13) in Kaivogen Red Buffer was added and the plate was 
incubated 1 h at RT in a shaker. The plate was washed four times with the wash buffer 
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and Kaivogen Enhancement solution was added and plate was again incubated for 10 
min at RT in a shaker. Time-resolved fluorescence of Europium was measured with Vic-
tor multilabel counter.  
For analyzing antigens against HPeV-1, the virus was coated onto plate like previously 
in the panning round three. After the incubation, the plate was washed three times with 
PBS. Phages were diluted to 10E13 in Red Kaivogen red assay Buffer (AB) and 200 µL 
per well of diluted phages were added onto plate. The plate was incubated 1 h at RT in 
a shaker and washed four times with PBS + 0.1 % Tween. Two hundred µL of labelled 
anti-phage antibody (125 ng/mL Eu-Mab) was added per well and the plate was incu-
bated 1 h at RT in a shaker. The plate was washed four times with the wash buffer and 
Kaivogen Enhancement solution was added 200 µL per well. The plate was incubated 
10 min at RT in a shaker and time-resolved fluorescence of Europium was measured 
with Victor multilabel counter. 
2.3 Cloning the enriched scFv library into screening vector pLK06FT 
Plasmid DNA isolation from glycerol preps (PR2-3) was done with Thermo Scientific Min-
iprep Kit. 
Isolation of vector XL1-Blue/pLK06FT was done with Thermo Scientific GeneJET Plas-
mid Midiprep Kit. Preculture of cells done in 50 mL SB medium with 0.5 % glucose, 100 
µg/mL of ampicillin and 10 µg/mL of tetracyclin. Cells were incubated overnight at 37 °C 
in 300 rpm shaker. 
DNA concentration for isolated phage plasmid DNA and vector were measured 
Nanodrop ND-1000 Spectrophotometer.  
Sfil digestions for the vector and plasmids were performed in Tango buffer over weekend 
at 50 °C. Eco01091 digestions were performed in Tango buffer at 37 °C for 4 h. 0.8 % 
agarose gel for analyzing the digestions was prepared. The gel was run 45 min with 60 
V. Midori green was used as coloring reagent and results were compared to DNA Ladder 
Thermo Scientific GeneRuler 1kb (Figure 6). A preparative gel for gel extraction of di-
gested vector pLK06FT was prepared. The gel was ran four hours with 50 V and two 
hours with 60 V. 500 bp band was isolated from the gel using scalpel and GeneJET Gel 
Extraction Kit was performed. The concentration of gel-purified vector pLK06FT was 
measured with Nanodrop. Ligations of the vector and scFv inserts were performed using 
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Fermentas T4DNA ligase buffer and T4 DNA-ligase. Control ligation without insert. Re-
agents were added and incubated 1 h at RT. The ligase was inactivated by incubating 
20 min at 65 °C and then put on ice. New vector pLK06FT-scFv can be seen in Figure 
7. 
2.3.1 Heat shock transformation with CaCl2 competent cells 
Heat shock transformation into CaCl2 competent E. Coli cells was performed using 50 
µL XL1 CaCl2 competent cells and 5 µL of each ligation reaction. Solutions were incu-
bated 30 min on ice, heat shocked at 42 °C for 90 s. Tubes were then put back on ice 
for 2 minutes after which 200 µL of SOC medium per tube was added and incubated in 
250 rpm at 37 °C for 1 h. Transformants were plated onto two LA plates with 0.5 % 
glucose and 100 µg/mL ampicillin. Plates were incubated overnight at 37 °C. Number of 
colonies was calculated. (Table 2) 
2.4 Screening of scFv production in microtiter wells 
Three plates (PR2, PR3 and PR3-HPeV-1) were prepared. 160 µL of SB medium with 1 
% glucose, 10 µg/mL tetracyclin and 100 µg/mL ampicillin was added in each well. Single 
colonies per every well were picked from transfection plates with sterile toothpicks. The 
microtiter plates were covered with breathable sealing tape and incubated overnight at 
26 °C with 900 rpm and 70 % moisture. The next morning 4 µL of cultures were inocu-
lated into new plates with fresh SB medium with 0.05 % glucose and the same antibiotics. 
The fresh plates were incubated at 37 °C with 900 rpm and 70 % moisture for 5 h until 
the cultures looked cloudy. Glycerol preps were made from overnight cultures by adding 
40 µL of 80 % glycerol per well and they were stored at -70 °C. After 5 hours of incubation 
cultures looked cloudy and protein production was induced by adding 20 µL of 2 mM 
IPTG in SB per well and incubated overnight at 26 °C with 900 rpm. 10x lysis buffer was 
prepared. 10x lysis buffer contained Alfa Aesar 10 mg/mL Lysozyme from chicken egg 
white and Merck Benzonase 1x100000U purity grade 2 (>90%) in 10x TBS pH 7,5. The 
lysis of cells was performed by adding 20 µL of 10x lysis buffer into each well and incu-
bating 30 min at RT. The plates were stored in -70 °C. 
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2.4.1 scFv-AP screening assay 
In total of 288 clones’ proteins were analyzed using scFv-AP assay. The assay was per-
formed for all three protein production plates. Two plates for each, one coated with bio-
GST as control and the second coated with bio-VP0-GST. Kaivogen streptavidin micro-
titration plate “normal” were used for coating. Streptavidin plates were prewashed and 
antigens for coating were used in a manner to reach saturation level of 25 %. Plates 
were incubated for 30 min at RT and washed four times with Kaivogen wash solution. 
180 µL of Kaivogen Red assay buffer was added in each well. Pelleted and lysed cells 
supernatants from the previous section were used as samples. 20 µL of samples were 
added in each well. Samples were incubated in slow shaking for 1 h at RT. Plates were 
then washed four times with Kaivogen wash buffer and 200 µL of 1 mg/mL pNPP in 
pNPP buffer was added into each well. Plates were incubated with slow shaking for 1h 
at RT. After one hour of incubation absorbance at 405 nm was measured with Victor. To 
clearer results, plates were incubated 2 h and measured absorbance again.  
2.4.2 Virus coating for scFv-AP screening 
4.5 µg of purified HPeV-1 was added on each well in 200 µL of 50 mM HCO3-/CO32+ 
buffer (pH 9.7) and the plate was incubated overnight at 4 °C. The plate was prewashed 
with PBS and blocked with PBS + 1 % BSA. The plate was incubated for 1 h on a shaker 
at RT and washed three times with PBS 0.1 % Tween. Phages were added onto plate in 
1:10 dilution in PBS + 1% BSA and the same buffer was used as background. The plate 
was incubated for 1 h on a shaker at RT. Wells were washed three times with PBS + 
1mM MgCl2. 1 mg/mL of pNPP in pNPP buffer was added onto wells and the plate was 
incubated for 1 h on a shaker at RT. Absorbance at 405 nm was measured and results 
corrected with blank. 
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2.4.3 Secondary culture and secondary scFv-AP screening assay 
Eighty-four out of 288 analyzed colonies with signals above cut-off value were picked for 
further analysis from the primary screening. Secondary screening was performed as the 
primary screening but in a larger scale (5 mL instead of a microtiter scale). 
2.4.4 Sequencing 
Plasmid DNA was isolated from 84 colonies with Thermo Scientific Miniprep Kit. Plasmid 
DNA and primers were pipetted on a plate which was then send to Macrogen for se-
quencing. Sequences were analyzed for CDR-3 region. 
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3 RESULTS 
3.1 Biotinylation of antigens 
To increase the specificity in the panning rounds, antigens were biotinylated. Absorbance 
at 280 nm was measured to see if biotinylation and buffer exchange had worked (Table 
1).  
Table 1 Antigen absorbance on wavelength 280 nm before and after biotinylation 
Antigen Original 
Absorbance (280 
nm) 
Absorbance (280 
nm) after 
biotinylation 
HPeV-1-VP0-GST 
 
0,569 0,127 
GST-control 
 
- 0,124 
3.2 Panning 
After three panning rounds, Eu-labelled Delfia was performed to see whether the VP0 
specific phage had been amplified or not. 
Figure 5 illustrates that panning rounds have been successful and phage titer specific to 
VP0 is amplified throughout the panning rounds. The background and GST in illustrate 
that phages did not bind to streptavidin or GST. After three panning rounds using VP0-
GST as antigen, phages that bind to purified HPeV-1 are not amplified but that can be 
due to the restrictions of assay used or the coating buffer pH being too high 
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3.3 Cloning 
ScFv fragments were subcloned from scFv phage library to the pLK06FT screening vec-
tor. That is, instead of subcloning scFv fragment from individual clones, phage DNA was 
isolated from phage display library preparation, scFv fragments from all phage particles 
were ligated into pLK06FT. To see the digestion efficiency an analytical gel was prepared 
and digested and undigested vectors were added to it with undigested and digested in-
serts marked with red circles (Figure 6).The picture illustrates the successful digestions 
of plasmids and vector, and that around 700 bp insert marked with red circle, is cut off 
from plasmid. After the ligation of the vector and the insert, the new vector should look 
like in Figure 7.  To verify the success of the ligation from plates after the heat shock 
transformation, a background vector ratio was calculated. The background vector ratio 
was calculated by comparing control plate readings without the insert to the plate with 
insert ligated into the vector.  
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Figure 5 Immunoassay results after panning rounds against SA, GST, VP0-GST and HPeV-1 
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From the left:  GeneRuler 1kb Ladder, digested vector, undigested vector, three digested 
plasmids, three undigested plasmids, Ladder 1kb 
 
Figure 6 an analytical agarose gel. 
 
 
 
Figure 7 pLK06FT-scFv after ligation. 
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Table 2 Plate readings after the heat shock transformation. 
 pLK06FT-
PR2/scFv 
pLK06FT-
PR3/scFv 
pLK06FT-
PR3Virus/scFv 
pLK06FT Control 
ligation 
25 µL plate 1 26 12 16 
The rest plate 753 600 600 5 
A background vector =a vector which does not have the insert = 
21
600
× 100% ≈ 3.5 % 
3.4 Screening 
Primary scFv-AP screening was performed to see how many binders against VP0 and 
HPeV-1 could be found. The assay is based on the fact that pNPP produces a yellow 
water-soluble reaction product that absorbs light at 405 nm when encountered with al-
kaline phosphatase which is produced with the scFvs. In total of 288 clones (96 per 
round) were picked from the transformation plates for the primary screening.  Secondary 
screening was performed to verify the primary screening results and to produce more 
antigens for further analysis. 
From the primary screening (Figure 8), 84 promising clones, marked with a red circle, 
were found which were further analyzed in the secondary screening (Figure 9). Eighty-
four hits out of 288 clones analyzed was a really promising result but it could be said that 
out of these 288 clones picked from the transformation plates, not nearly all different 
clones was found (
84
288
× 1991 = 580). Eighty-four clones was a number that could easily 
be tested further. The secondary screening results are not that good as primary screen-
ing results but it can be seen that the 84 picked clones have properties to bind against 
VP0 or HPeV-1. In the secondary screening after 3 h incubation graph, the first 31 orig-
inal absorbance values are picked from the o/n incubation and that is why the absorb-
ance on them is so high. In the secondary screening done against HPeV-1, the results 
are not optimal even with the pNPP incubation of over weekend. Still from the graph it is 
visible that phages amplified in panning rounds have properties to bind against purified 
HPeV-1. The first 31 hits in Figure 9 in HPeV-1 graph are from the panning round three, 
the next 9 are from the panning round two and the last 44 are from the panning round 
three done with HPeV-1. The interesting part is that phages from the panning round two 
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against VP0 had more binders against the HPeV-1 than the panning round three against 
the VP0.  
 
 
 
Figure 8 Primary screening results against VP0 and HPeV-1. 
18 
 
 
 
Figure 9 Secondary screening results against VP0-GST and HPeV-1. 
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3.5 Sequencing 
The sequence data was compared with the secondary screening results (Table 3) and 
12 different CDR-H3 clone groups, which detected either VP0 or HPeV-1 in secondary 
screening, were found. From the 84 DNA samples send to sequencing, 16 in total had 
some errors which made reliable sequencing impossible, eight of them had more than 
one sequence.  Forty out of 84 samples had strong interaction with VP0 in secondary 
screening. Twenty out of these 40 were from two different CDR-H3 clone group named 
CTGWAY and CASGAV. Both of them are groups, which have been present in every 
panning round. The remaining 20 consisted of three main groups CAAESFRGGAY, 
CASGYI and CATAWLEY and of five individual clones and of one group which recog-
nized only HPeV-1 but not the VP0. 
Table 3 Sequencing data against 2nd screening data 
 
  
CDR Groupname 2nd screening Abs405 - background CDR Groupname 2nd screening Abs405 - background
CAAESFRGGAY 1,3395 CATAWLEY 0,9465
CAAESFRGGAY 1,1955 CATAWLEY 0,928
CAAESFRGGAY 0,8685 CATAWLEY 0,8325
CAAESFRGGAY 0,7835 CATAWLEY 0,78
CAAESFRGGAY 0,761 CATAWLEY 0,674
CAKTYVDWYLDY 0,865 CATAWLEY 0,5745
CARESWTSLSPDY 1,186 CTGWAY 1,4985
CARGATNRFAY 0,6145 CTGWAY 1,411
CARGIFDL 0,5345 CTGWAY 1,391
CARRYVGNYLDY 0,645 CTGWAY 1,2725
CASGAV 1,269 CTGWAY 0,8955
CASGAV 1,242 CTGWAY 0,8875
CASGAV 1,1845 CTGWAY 0,8625
CASGAV 1,1395 CTGWAY 0,616
CASGAV 1,1205 CTGWAY 0,572
CASGAV 1,0985 CTGWAY 0,514
CASGAV 0,9455 Error 0,9045
CASGAV 0,766 Error 0,865
CASGAV 0,736 Error 0,7915
CASGAV 0,6555 Error 0,781
CASGAY 1,0395 Error 0,647
CASGYI 2,058 Error 0,615
CASGYI 1,282 Error 0,5275
CASGYI 0,536
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4 DISCUSSION 
In this study, human parechovirus 1 recombinant protein VP0 and CsCl-purified HPeV-
1 particles were used in phage display as a target to find binders against. The first two 
panning rounds were performed with VP0-GST and the last round with HPeV-1. When 
comparing results from the panning round three VP0 against the panning round three 
done with HPeV-1 it seems to be clear that by doing the last round of phage display with 
the virus one can find more binders which recognize also VP0. Forty-four of 84 clones 
analyzed in the secondary screening were from the last panning round with the virus. In 
general, panning rounds were successful, which is evident from the screening results. 
Signals intensified as the panning rounds went further which supports the fact that 
phages specific to VP0-GST were amplified (Figure 9). 
In the secondary large scale culture of 84 clones, the protein production seemed to have 
some problems, which can be seen in the graph comparing the primary screening done 
in 96-well plate results (Figure 8) to 5 mL culture results (Figure 9). Figure 9 illustrates 
large scale signals being very much lower than in the smaller scale. 
At this stage of the project, clones with 12 different CDR-H3 regions were identified. The 
representative clones should be cultivated in larger volumes, and further analyzed for 
their functionality in immunofluorescence assay and virus neutralization. Furthermore, 
binding to different HPeV types as well as HPeV-1 clinical isolates should be examined. 
The most prominent clones may be subjects of affinity maturation to improve the binding 
properties. 
 
 
 
21 
 
REFERENCES 
Lutwick Larry I 2014. Picornavirus overview Medscape 14.4.2016 http://emedicine.med-
scape.com/article/225483-overview#a4 
Wolthers, KC; Benschop, KS; Schinkel, J; Molenkamp, R; Bergevoet, RM; Spijkerman, IJ; Kraak-
man, HC & Pajkrt, D. 2008. Human parechoviruses as an important viral cause of sepsislike ill-
ness and meningitis in young children. Clin. Infect. Dis. 47 Pages 358 – 363. 14.4.2016 PubMed 
Joki-Korpela, P. & Hyypiä T. 2001. Parechoviruses, a novel group of human picornaviruses. Ann 
Med 33, Pages 466 – 471. 
ViralZone 8.4.2016 http://viralzone.expasy.org/all_by_species/33.html 
Hoogenboom, HR; de Bruïne, AP; Hufton, SE; Hoet, RM; Arends, J-W & Roovers, RC. June 1998 
Antibody phage display technology and its applications. Immunotechnology Volume 4 Issue 1 
Pages 1 – 20. 
Huovinen, T; Syrjänpää, M; Sanmark, H; Brockmann, EC; Azhayev, A; Wang, Q; Vehniäinen, M 
& Lamminmäki, U. July 2013. Two ScFv antibody libraries derived from identical VL-VH frame-
work with different binding site designs display distinct binding profiles, Oxford Journals Protein 
Engineering, Design & Selection Volume 26, Issue 10 pages 683 – 693. 
Carmen, S & Jermutus, L. July 2002 Concepts in antibody phage display, Briefings in functional 
genomics and proteomics Volume 1, Number 2, Pages 180 – 203. 
 
 
Appendix (1) 
Picornavirus family tree 
 
Picornaviridae family (Wikipedia) 
 
 
